Har­mo­ny Bio­sciences' Wak­ix fails PhI­II hy­per­som­nia study; Flori­da gene ther­a­py start­up down­sizes

Plus Phase II da­ta on ABION’s MET ty­ro­sine ki­nase in­hibitor, and 60 De­grees Phar­ma­ceu­ti­cals giv­ing up on re­pur­pos­ing its an­ti­malar­i­al drug for Covid-19.

Har­mo­ny Bio­sciences’ drug failed the pri­ma­ry goal in a Phase III study and in­vestors re­act­ed by shed­ding the biotech’s share price $HRMY by about 30% Fri­day morn­ing. The Penn­syl­va­nia drug­mak­er said its treat­ment can­di­date pitolisant did not achieve sta­tis­ti­cal sig­nif­i­cance on ex­ces­sive day­time sleepi­ness in the ran­dom­ized with­draw­al phase of the IN­TUNE study, which in­cludes pa­tients with the rare and chron­ic dis­ease id­io­path­ic hy­per­som­nia. The FDA ap­proved the tablets, sold as Wak­ix, in 2019 to treat ex­ces­sive day­time sleepi­ness in adults with nar­colep­sy. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER